While a recent head-to-head trial of the obesity med heavyweights Wegovy and Zepbound favored the latter drug from Eli Lilly on weight loss, Novo Nordisk has now countered that result with ...
Novo Nordisk (NVO) (OTCPK:NONOF) announced on Sunday that its popular weight loss drug Wegovy resulted in more than a 50% decrease in serious heart issues such as stroke compared to Eli Lilly’s ...
A class-action lawsuit accuses CVS Caremark of denying medically necessary treatments by stopping coverage of Zepbound, Eli Lilly’s blockbuster weight-loss drug. CVS Caremark stopped covering Zepbound ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback